Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Tamm
Ingo
I
Dept. of Hematology and Oncology, Wirchow-Clinic, Humboldt-University of Berlin, Germany. ingo.tamm@charite.de
D000970:Antineoplastic Agents / Q000494:pharmacology*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D015687:Cell Hypoxia / Q000187:drug effects*; D003035:Cobalt / Q000494:pharmacology*; D003676:Deferoxamine / Q000494:pharmacology*; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D009363:Neoplasm Proteins / Q000378:metabolism; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D010087:Oxides / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology / Q000627:therapeutic use; D020298:U937 Cells / Q000187:drug effects
D000970:Antineoplastic Agents; D001152:Arsenicals; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D010087:Oxides; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D003035:Cobalt; D014212:Tretinoin; C018021:cobaltous chloride; D003676:Deferoxamine; D000077237:Arsenic Trioxide